Dr Yehuda Handelsman Discusses New Alternatives to Basal Insulin

Recent advances in insulin formulations and innovative drug classes have made it easier than ever to manage diabetic patients’ glucose levels, according to Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America.

Related Videos

Related Content

Advertisement

August 2nd 2025

Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021

Elise S. Tremblay, MD, MPH Stephanie Argetsinger, MS, MPH Fang Zhang, PhD Dennis Ross-Degnan, ScD J. Frank Wharam, MD, MPH

Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.

August 2nd 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

August 2nd 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

August 2nd 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.

August 2nd 2025

Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.

August 2nd 2025

SGLT2i-Induced Erythrocytosis Not Linked to Clots in Type 2 Diabetes

Pearl Steinzor

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 inhibitor (SGLT2i) users with type 2 diabetes, study finds.

Related Content

Advertisement

August 2nd 2025

Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021

Elise S. Tremblay, MD, MPH Stephanie Argetsinger, MS, MPH Fang Zhang, PhD Dennis Ross-Degnan, ScD J. Frank Wharam, MD, MPH

Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.

August 2nd 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

August 2nd 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

August 2nd 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.

August 2nd 2025

Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.

August 2nd 2025

SGLT2i-Induced Erythrocytosis Not Linked to Clots in Type 2 Diabetes

Pearl Steinzor

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 inhibitor (SGLT2i) users with type 2 diabetes, study finds.